Comparative Metabolism of a GalNAc-Conjugated siRNA, Inclisiran, Among Various In Vitro Systems and Correlations with In Vivo Metabolism in Rats - WuXi AppTec DMPK

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.

Contact Us

What can we help you find?

Top Searches

PROTAC

ADC

RNA

ADME

OLIGO

Comparative Metabolism of a GalNAc-Conjugated siRNA, Inclisiran, Among Various In Vitro Systems and Correlations with In Vivo Metabolism in Rats

  • Publications

  • May 08, 2025

◢ ASRET, Articles in Press, 100089, April 29, 2025


Hong Zhang, Gengyao Qin, Liqi Shi, Ruixing Li, Liang Shen, Weiqun Cao, Yi Tao 


DMPK Service Department, WuXi AppTec, Shanghai, China




Abstract:


GalNAc-conjugated small interfering RNAs (siRNAs) have emerged as a promising new class of therapeutics, demonstrating potential across various disease areas. Metabolic stability is a critical factor in the development of siRNA therapies, necessitating the selection of suitable in vitro metabolism models for comprehensive studies. However, many existing in vitro models often fail to accurately predict in vivo metabolism. Therefore, our objective was to systematically identify the optimal models and conditions that can simulate in vivo metabolism. Inclisiran, a representative GalNAc-conjugated siRNA, was chosen as the model compound for this investigation. A thorough comparison of in vitro metabolism was conducted to identify optimal models and corresponding conditions that could predict Inclisiran's metabolic profiles in rat plasma and liver in vivo. The models tested included serum, plasma, plated hepatocytes, liver homogenate, S9 fractions, tritosomes, lysosomes, and cytosol, reflecting Inclisiran's trajectory from injection to RNA-induced silencing complex (RISC) in hepatocytes. The results indicated that both rat serum and heparin-anticoagulant plasma are suitable models to mimic the nucleolytic metabolism of Inclisiran in in vivo blood. For hepatic metabolism, liver homogenate in phosphate buffer (pH 6.0), liver tritosomes in acetate buffer (pH 5.0), and plated hepatocytes were suitable models. Liver homogenate and cytosol in Tris-HCl buffer (pH 7.4) were effective for studying nuclease-mediated metabolism of Inclisiran's antisense strand under neutral conditions, though they did not fully simulate in vivo metabolism of the sense strand. These findings underscore the importance of selecting appropriate in vitro models and conditions to accurately simulate in vivo metabolism of Inclisiran.


Keywords


GalNAc-conjugated siRNA; Inclisiran; metabolic stability; metabolite profiling; metabolism; in vitro-in vivo correlation

Stay Connected

Keep up with the latest news and insights.

  • Email address*

    * Please check the filled content
  • First name*

    * Please check the filled content
  • Last name*

    * Please check the filled content
  • Company*

    * Please check the filled content

By clicking submit, you consent to WuXi AppTec DMPK collecting and processing the information you provide for our internal purposes, in accordance with our privacy policy.

* Please agree to the Privacy Policy

Thanks for signing up

Help us get to know you better! By customizing your email preferences, we can deliver curated content relevant to you.